
About
Prior to joining ADIA, Mr. Higgins served as Consultant to Blackstone Healthcare Partners of The Blackstone Group from June 2010 until June 2021. He also served as non-executive chairman of the board of Assertio Holdings, Inc., successor issuer to Assertio Therapeutics, Inc., from May 2020 until December 2020. Prior to that, he served as President, Chief Executive Officer and a member of the board of directors of Assertio Therapeutics, Inc. from March 2017 until its merger with Zyla Life Sciences in May 2020. Previously, Mr. Higgins served as Chairman of the Board of Management of Bayer HealthCare AG from January 2006 to May 2010 and Chairman of the Bayer HealthCare Executive Committee from July 2004 to May 2010. Prior to joining Bayer HealthCare in 2004, Mr. Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 to 2004. Prior to that, Mr. Higgins spent 14 years with Abbott Laboratories, most recently as President of the Pharmaceutical Products Division from 1998 to 2001. He is past member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (“PHRMA”), Council member of the International Federation of Pharmaceutical Manufacturers (“IFPMA”) and President of the European Federation of Pharmaceutical Industries Association (“EFPIA”). He graduated from Strathclyde University, Scotland and holds a B.S. in biochemistry.
Personal Details
Qualifications & Experience
Other directorships (state)
(only entities turnover at least $5m p/a)
Working history
Committee/s
| Company | Committee | Role | Appointment Date | Resignation Date |
|---|---|---|---|---|
| Ecolab | Board | Member | 01/01/2010 | |
| Ecolab | Capital investment | Member | 01/01/2010 | |
| Ecolab | Health, Safety & Environment | Member | 01/01/2010 | |
| Ecolab | Remuneration | Member | 01/01/2010 |